Weekly roundup: May the ‘4th’ be with you! May the ‘4th’ be with you! (Sorry – we couldn’t help ourselves.) The force of innovation was strong across the life sciences sector this week. The Optimum team joined leaders from across the industry at this year’s BioEquity Europe conference in Prague, where discussions reflected the sector’s […]
PDUFA action date for Hansa Biopharma’s imlifidase BLA set for December 19, 2026 Hansa Biopharma announced that the Food and Drug Administration (FDA) has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been assigned a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2026. 📺Optimum TV […]
Novo Nordisk Foundation announced it had awarded DKK 11.8 billion (€1.6 billion) during 2025 to support more than 2,200 projects aimed at improving people’s health and the sustainability of society and the planet. The projects cover the full range of the Foundation’s grant-giving areas, including key topics such as cardiometabolic diseases, antimicrobial resistance, the development of more resilient and climate-friendly […]
JPM 2026 was touted as the event that would usher in the best year in biotech in a long time. But when it happened there was a distinct lack of mega-deals to shout about. The elephant, you might say, was not in the room. Does this bode ill for 2026? Or is news of such […]
People in Europe and the US rarely pay for prescription drugs out of their own pockets. In Europe, their national health services almost always pick up the tab – even if some people have to contribute by way of a prescription charge. In the US, the health insurer normally foots the bill. But things have […]
